+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

R

Actively Recruiting

This research aims to evaluate the clinical effectiveness, safety, and tolerability of XEN1101 when used alongside other antiseizure medications in adults with focal-onset seizures. It is a Phase 3, randomized, double-blind, placebo-controlled study involving approximately 360 participants. The study focuses on how XEN1101 affects seizure frequency compared to placebo while monitoring any side effects or safety concerns. Participants will be randomly assigned to one of three groups XEN1101 25 mg, XEN1101 15 mg, or placebo, taken once daily with an evening meal. The study includes a baseline period of up to 9.5 weeks to record seizure frequency, followed by 12 weeks of blinded treatment. After this, those who complete the treatment phase may join an open-label extension study for continued XEN1101 treatment, while others will enter an 8-week post-treatment follow-up period. During the study, participants will keep accurate seizure diaries and attend regular visits for assessments including seizure monitoring, safety checks, and tolerability evaluations. Researchers will measure the median percent change in focal seizure frequency from baseline through the 12-week treatment, along with other outcomes such as the proportion of participants experiencing significant seizure reduction and patient-reported global impressions. Safety is monitored from screening through 56 days after the final dose to ensure participant well-being throughout the trial.

Age: 18Years +All GendersPhase 3
103 locations
L

Actively Recruiting

Researchers are evaluating the safety and tolerability of TAK-861 in people with narcolepsy type 1 NT1. This study focuses on participants who have already been exposed to TAK-861 doses in previous clinical trials. The goal is to monitor how TAK-861 affects symptoms such as excessive daytime sleepiness and cataplexy episodes over a long period. All participants in this trial will receive TAK-861 tablets. Those who previously received a placebo will be randomly assigned to one of the TAK-861 dose groups. The study is a long-term extension conducted worldwide and is expected to last approximately five years or until the product is approved or the study is stopped. Participants may switch doses as needed and will attend multiple clinic visits, some of which can be done at home. Throughout the trial, participants will be regularly assessed for safety by tracking any treatment-emergent adverse events. Researchers will also measure changes in sleep latency, sleepiness scores, and cataplexy rates compared to baseline data from earlier trials. Follow-up assessments will take place four weeks after the final dose to monitor ongoing effects and ensure participant safety.

Age: 16Years - 70YearsAll GendersPhase 2Phase 3
52 locations
E

Actively Recruiting

Researchers are evaluating ALKS 2680 tablets in adults with Narcolepsy Type 1 NT1 to measure reductions in daytime sleepiness, sudden muscle tone loss cataplexy, and overall disease symptoms. This phase 3 clinical trial compares the effects of ALKS 2680 with placebo tablets to assess their impact on these key aspects of NT1. Participants are randomly assigned to one of three groups a placebo group or one of two different dose groups of ALKS 2680 tablets. All participants take their assigned oral tablets daily for 12 weeks. The study uses a triple-blind design, meaning that participants, investigators, and others involved do not know which treatment is being given. During the 12-week treatment, participants will be monitored for changes in sleep latency using the Maintenance of Wakefulness Test, daytime sleepiness via the Epworth Sleepiness Scale, weekly cataplexy rates, and other cognitive and fatigue assessments. Safety is tracked through the incidence of treatment-emergent adverse events up to 14 weeks. Outcome measures also include patient global impressions and narcolepsy severity scales to evaluate overall disease impact.

Age: 18Years - 70YearsAll GendersPhase 3
44 locations
E

Actively Recruiting

Researchers are evaluating the effects of ALKS 2680 tablets on reducing daytime sleepiness and symptoms in adults diagnosed with Narcolepsy Type 2 NT2. This Phase 3, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of three different doses of ALKS 2680 compared with placebo tablets. The study is sponsored by Alkermes, Inc. and uses a parallel design to compare outcomes. Participants are randomly assigned to receive one of three dose levels of ALKS 2680 tablets or a placebo, taken orally once daily for 12 weeks. The study includes a triple-blind approach to ensure unbiased results. The primary focus is on measuring changes in mean sleep latency using the Maintenance of Wakefulness Test MWT from baseline through Week 12. Secondary outcome measures include assessments of sleepiness, cognitive complaints, fatigue, and global impression scales. Throughout the 12-week treatment, participants will undergo various evaluations such as the Epworth Sleepiness Scale, Patient Global Impression-Severity scale, and Psychomotor Vigilance Task, among others. Safety is monitored by recording treatment emergent adverse events up to 14 weeks. This study includes adults aged 18 to 70 years with a confirmed diagnosis of NT2. Overall participation spans just over 12 weeks, with regular assessments to track symptom changes and treatment effects.

Age: 18Years - 70YearsAll GendersPhase 3
44 locations
E

Actively Recruiting

Researchers are evaluating XEN1101 as an additional treatment for people with primary generalized tonic-clonic seizures PGTCS in this Phase 3, multicenter, randomized, double-blind, placebo-controlled trial. The study aims to assess the clinical efficacy, safety, and tolerability of XEN1101 in subjects diagnosed with generalized epilepsy who are currently taking 1 to 3 anti-seizure medications ASMs. Participants must have probable or possible PGTCS and meet specific inclusion criteria. Participants aged 12 years and older will be randomly assigned to receive either XEN1101 or a placebo. Those 18 years and older will receive 25 mg of XEN1101 or placebo daily, while those between 12 and under 18 years may receive 15 mg, 25 mg, or placebo once daily with an evening meal. The study includes a baseline period lasting up to 9.5 weeks to monitor seizure frequency, followed by a 12-week double-blind treatment period. After completing this phase, participants can enter an open-label extension study to continue XEN1101 treatment or join an 8-week post-treatment follow-up. Throughout the study, participants will keep accurate seizure diaries and undergo assessments to measure the median percent change in monthly PGTCS frequency. The study will also monitor safety and tolerability during treatment. Those who do not continue into the extension phase will have follow-up visits for 8 weeks after treatment ends. Overall, the trial involves multiple visits and careful monitoring to evaluate the impact of XEN1101 as adjunctive therapy over several months.

Age: 12Years +All GendersPhase 3
141 locations
O

Actively Recruiting

Researchers are evaluating how the drug cenobamate affects healthcare resource use for adults with epilepsy who have uncontrolled focal onset seizures. This observational, retrospective study compares medical resource use before and after patients start cenobamate as an additional therapy because previous anti-seizure medications were not effective or tolerable. Data from medical charts of 200 patients across 10 sites in 5 countries will be collected and analyzed. The study focuses on adult patients who began treatment with cenobamate as adjunctive therapy according to approved guidelines. Patients included have uncontrolled focal seizures despite 2 to 5 prior anti-seizure medications and have at least 6 months of data before starting cenobamate and 12 months of data afterward. This retrospective chart review gathers real-world data without altering patient treatment. Participants medical records will be reviewed for healthcare resource use related to epilepsy, including hospital visits, emergency care, medication use, surgeries, and phone or virtual contacts over a 12-month period before and after starting cenobamate. Researchers will also assess safety data and how concomitant anti-seizure medications change. The study is conducted under data protection regulations and will provide insights into the impact of cenobamate on managing uncontrolled focal seizures.

Age: 18Years +All Genders
10 locations